Nuclide Therapeutics
British BioTech company and King’s College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers
Nuclide Therapeutics has raised €5.7M across 1 funding round from 1 investor, most recently a round in Sep 2025. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKnuclidetx.com ↗
Total raised
€5.7M
€5,700,000
Funding rounds
1
Investors
1
distinct backers
Active since
2025-09
latest 2025-09
Funding by year
EUR raised per yearNuclide Therapeutics — funding by year — interactive chart.
Data table
| Nuclide Therapeutics — funding by year | |
|---|---|
| 2025 | €5.7M |
Signals
High confidenceRaise-next likelihood42
base rate 30% for Other
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-23 | Other | €5.7M | Marathon Beteiligungs AG | View deal → |